靶向分子伴侣热休克蛋白90对癌细胞的多种细胞信号通路具有多方面的影响。 - Suppr

Suppr

超能文献

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.

作者信息

Xu Wanping, Neckers Len

机构信息

Urologic Oncology Branch, National Cancer Institute, Bethesda, MD 20892-1107, USA.

出版信息

Clin Cancer Res. 2007 Mar 15;13(6):1625-9. doi: 10.1158/1078-0432.CCR-06-2966.

DOI:10.1158/1078-0432.CCR-06-2966

PMID:17363512

Abstract

摘要

相似文献

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.

Clin Cancer Res. 2007 Mar 15;13(6):1625-9. doi: 10.1158/1078-0432.CCR-06-2966.

Heat shock protein 90: a unique chemotherapeutic target.

Semin Oncol. 2006 Aug;33(4):457-65. doi: 10.1053/j.seminoncol.2006.04.001.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. doi: 10.1677/erc.1.01324.

Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.

J Med Chem. 2006 Dec 28;49(26):7721-30. doi: 10.1021/jm060836y.

Hsp90: the vulnerable chaperone.

Drug Discov Today. 2004 Oct 15;9(20):881-8. doi: 10.1016/S1359-6446(04)03245-3.

Heat shock protein 90 as a drug target: some like it hot.

Clin Cancer Res. 2009 Jan 1;15(1):9-14. doi: 10.1158/1078-0432.CCR-08-0132.

[Hsp90--a target for anticancer therapy].

Klin Onkol. 2011;24(5):329-37.

Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.

Proteomics. 2007 Aug;7(15):2603-16. doi: 10.1002/pmic.200700108.

[Drug resistance mediated by survival- and growth-promoting signaling pathways].

Gan To Kagaku Ryoho. 2009 Apr;36(4):567-71.

Inhibition of HSP70: a challenging anti-cancer strategy.

Cancer Lett. 2012 Dec 28;325(2):117-24. doi: 10.1016/j.canlet.2012.06.003. Epub 2012 Jun 28.

引用本文的文献

Inhibiting HSP90 changes the expression pattern of PINK1 and BNIP3 and induces oxidative stress in colon cancer cells.

Mol Biol Rep. 2025 Feb 8;52(1):212. doi: 10.1007/s11033-025-10303-x.

Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy.

Transl Oncol. 2025 Feb;52:102237. doi: 10.1016/j.tranon.2024.102237. Epub 2024 Dec 12.

PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.

Front Pharmacol. 2024 Nov 5;15:1475998. doi: 10.3389/fphar.2024.1475998. eCollection 2024.

Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.

Genes (Basel). 2024 Jan 22;15(1):137. doi: 10.3390/genes15010137.

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.

Cancer. 2023 Jun 15;129(12):1904-1918. doi: 10.1002/cncr.34730. Epub 2023 Apr 11.

MicroRNA-570 targets the HSP chaperone network, increases proteotoxic stress and inhibits mammary tumor cell migration.

Sci Rep. 2022 Sep 16;12(1):15582. doi: 10.1038/s41598-022-19533-6.

Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts.

BMC Musculoskelet Disord. 2022 May 26;23(1):495. doi: 10.1186/s12891-022-05419-1.

Studies on Preformulation and Formulation of JIN-001 Liquisolid Tablet with Enhanced Solubility.

Pharmaceuticals (Basel). 2022 Mar 28;15(4):412. doi: 10.3390/ph15040412.

Extracellular HSPs: The Potential Target for Human Disease Therapy.

Molecules. 2022 Apr 6;27(7):2361. doi: 10.3390/molecules27072361.

A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.

Theranostics. 2022 Jan 1;12(1):105-125. doi: 10.7150/thno.63788. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.

作者信息

Xu Wanping, Neckers Len

机构信息

Urologic Oncology Branch, National Cancer Institute, Bethesda, MD 20892-1107, USA.

出版信息

Clin Cancer Res. 2007 Mar 15;13(6):1625-9. doi: 10.1158/1078-0432.CCR-06-2966.

DOI:10.1158/1078-0432.CCR-06-2966

PMID:17363512

Abstract

摘要

相似文献

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.

Clin Cancer Res. 2007 Mar 15;13(6):1625-9. doi: 10.1158/1078-0432.CCR-06-2966.

Heat shock protein 90: a unique chemotherapeutic target.

Semin Oncol. 2006 Aug;33(4):457-65. doi: 10.1053/j.seminoncol.2006.04.001.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. doi: 10.1677/erc.1.01324.

Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.

J Med Chem. 2006 Dec 28;49(26):7721-30. doi: 10.1021/jm060836y.

Hsp90: the vulnerable chaperone.

Drug Discov Today. 2004 Oct 15;9(20):881-8. doi: 10.1016/S1359-6446(04)03245-3.

Heat shock protein 90 as a drug target: some like it hot.

Clin Cancer Res. 2009 Jan 1;15(1):9-14. doi: 10.1158/1078-0432.CCR-08-0132.

[Hsp90--a target for anticancer therapy].

Klin Onkol. 2011;24(5):329-37.

Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.

Proteomics. 2007 Aug;7(15):2603-16. doi: 10.1002/pmic.200700108.

[Drug resistance mediated by survival- and growth-promoting signaling pathways].

Gan To Kagaku Ryoho. 2009 Apr;36(4):567-71.

Inhibition of HSP70: a challenging anti-cancer strategy.

Cancer Lett. 2012 Dec 28;325(2):117-24. doi: 10.1016/j.canlet.2012.06.003. Epub 2012 Jun 28.

引用本文的文献

Inhibiting HSP90 changes the expression pattern of PINK1 and BNIP3 and induces oxidative stress in colon cancer cells.

Mol Biol Rep. 2025 Feb 8;52(1):212. doi: 10.1007/s11033-025-10303-x.

Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy.

Transl Oncol. 2025 Feb;52:102237. doi: 10.1016/j.tranon.2024.102237. Epub 2024 Dec 12.

PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.

Front Pharmacol. 2024 Nov 5;15:1475998. doi: 10.3389/fphar.2024.1475998. eCollection 2024.

Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.

Genes (Basel). 2024 Jan 22;15(1):137. doi: 10.3390/genes15010137.

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.

Cancer. 2023 Jun 15;129(12):1904-1918. doi: 10.1002/cncr.34730. Epub 2023 Apr 11.

MicroRNA-570 targets the HSP chaperone network, increases proteotoxic stress and inhibits mammary tumor cell migration.

Sci Rep. 2022 Sep 16;12(1):15582. doi: 10.1038/s41598-022-19533-6.

Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts.

BMC Musculoskelet Disord. 2022 May 26;23(1):495. doi: 10.1186/s12891-022-05419-1.

Studies on Preformulation and Formulation of JIN-001 Liquisolid Tablet with Enhanced Solubility.

Pharmaceuticals (Basel). 2022 Mar 28;15(4):412. doi: 10.3390/ph15040412.

Extracellular HSPs: The Potential Target for Human Disease Therapy.

Molecules. 2022 Apr 6;27(7):2361. doi: 10.3390/molecules27072361.

A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.

Theranostics. 2022 Jan 1;12(1):105-125. doi: 10.7150/thno.63788. eCollection 2022.